Please assess the completion status of the following clinical trial:

Trial Title: Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females between the ages of 18 and 60~2. Current DSM-V diagnosis of PTSD comorbid with MDD~3. CAPS-5 ≥ 25, and 17-item HRSD ≥ 17~4. Able to give consent, fluent in English~Exclusion Criteria:~1. Prior or current diagnosis with traumatic brain injury, bipolar disorder, psychotic disorder, gambling or impulse control disorders, or dementia~2. History of psychosis, psychotic disorder, mania or bipolar disorder~3. Severe substance use disorder excluding nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are accepted)~4. Individuals at risk for suicide based on history and current mental state. BDI-II suicide item \> 2 or CGI-Severity baseline score of 7.~5. Treatment with antidepressants or other psychotropic medication in the past 4 weeks (or 6 weeks for fluoxetine; an exception will be made for zolpidem used intermittently for sleep).~6. Pregnancy or plans to become pregnant during the period of the study.~7. Current psychotherapy~8. Current unstable or untreated medical illness~9. Any condition that would exclude clinical MRI exam (e.g. pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos, severe obesity, claustrophobia)~10. History of untoward reaction to pramipexole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PE/Pramipexole (Type: EXPERIMENTAL): Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).